Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants

Lorlatinib, a selective inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinase, is indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC) following progression on crizotinib and at least one other ALK inhibitor, or alectinib/cerit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Joseph, Houk, Brett, Pithavala, Yazdi K., Ruiz‐Garcia, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894400/
https://www.ncbi.nlm.nih.gov/pubmed/33449423
http://dx.doi.org/10.1002/psp4.12585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894400/
https://www.ncbi.nlm.nih.gov/pubmed/33449423
http://dx.doi.org/10.1002/psp4.12585

Ejemplares similares